BiVictriX posts promising preclinical data on leukaemia candidate

Biotechnology company BiVictriX Therapeutics updated the market on the pre-clinical evaluation of BVX001 on Thursday - its first-in-class ‘Bi-Cygni’ antibody drug conjugate (ADC) developed for the potential treatment of acute myeloid leukaemia (AML).

Related Keywords

, Bivictrix Therapeutics , Bivictrix , Posts , Promising , Preclinical , Data , Leukaemia , Candidate , Category All , Category Market Report , Category Company News , Category News And Announcements , Category Small Caps News , Category Aim Bulletin , Category Tecnologia , Category Market Pulse ,